Tilray, Inc. is dedicated to the research, cultivation, processing and distribution of medical cannabis. The company offers its products to patients, doctors, clinics, pharmacies, governments and hospitals.
The Ministry of Health and the New Zealand Medicinal Cannabis Agency grant Tilray the first approval under the new Medicinal Cannabis Plan to launch medicinal cannabis products across the country, which will undoubtedly have a major impact on revenue of the company.
During the week, most sectors showed a recovery, however, the marijuana companies had a controlled upside and this is likely to continue. We consider that Tilray is in the middle of its journey.
Technical:
- Average RSI levels
- Buying force 143M buying volume last week.
- Bounce on MA100
The Ministry of Health and the New Zealand Medicinal Cannabis Agency grant Tilray the first approval under the new Medicinal Cannabis Plan to launch medicinal cannabis products across the country, which will undoubtedly have a major impact on revenue of the company.
During the week, most sectors showed a recovery, however, the marijuana companies had a controlled upside and this is likely to continue. We consider that Tilray is in the middle of its journey.
Technical:
- Average RSI levels
- Buying force 143M buying volume last week.
- Bounce on MA100
Trade closed: stop reached
23 Mar
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.